CKLSF (CK Life Sciences International Holdings) Operating Income: $-16.8 Mil (TTM As of Dec. 2025)


CKLSF CK Life Sciences International Holdings Inc CKLSF
34 GF Score
Price $0.09
GF Value $0.11
! 5 Warning Signs
View Full Analysis

What is CK Life Sciences International Holdings Operating Income?

CK Life Sciences International Holdings CKLSF +28.57% 34 Operating Income is $-16.8 Mil as of Dec. 2025. GuruFocus rates CKLSF with a GF Score™ of 34/100 and a GF Value™ of $0.11. The stock has 5 warning signs investors should review.

CK Life Sciences International Holdings's Operating Income for the six months ended in Dec. 2025 was $-12.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $-16.8 Mil.

Warning Sign:

CK Life Sciences International Holdings Inc has recorded a loss in operating income at least once over the past 3 years.

Operating Margin % is calculated as Operating Income divided by its Revenue. CK Life Sciences International Holdings's Operating Income for the six months ended in Dec. 2025 was $-12.5 Mil. CK Life Sciences International Holdings's Revenue for the six months ended in Dec. 2025 was $360.4 Mil. Therefore, CK Life Sciences International Holdings's Operating Margin % for the quarter that ended in Dec. 2025 was -3.47%.

CK Life Sciences International Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CK Life Sciences International Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. CK Life Sciences International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.80%.


CK Life Sciences International Holdings  (OTCPK:CKLSF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CK Life Sciences International Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-25.022 * ( 1 - 100% )/( (1220.639 + 1506.432)/ 2 )
=-0/1363.5355
=0.00 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1438.035 - 115.742 - ( 101.654 - max(0, 269.978 - 401.099+101.654))
=1220.639

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1521.253 - 74.093 - ( 77.507 - max(0, 445.708 - 386.436+77.507))
=1506.432

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

CK Life Sciences International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=61.802/( ( (339.725 + max(183.703, 0)) + (349.784 + max(173.935, 0)) )/ 2 )
=61.802/( ( 523.428 + 523.719 )/ 2 )
=61.802/523.5735
=11.80 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(135.751 + 162.512 + 1.182) - (115.742 + 0 + 0)
=183.703

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(124.254 + 158.145 + 22.556) - (74.093 + 0 + 56.927)
=173.935

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

CK Life Sciences International Holdings's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-12.511/360.428
=-3.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


CK Life Sciences International Holdings Operating Income Related Terms


CK Life Sciences International Holdings Operating Income Historical Data

* Premium members only.

The historical data trend for CK Life Sciences International Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CK Life Sciences International Holdings Operating Income Chart

CK Life Sciences International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.92 31.10 28.66 9.97 -16.84

CK Life Sciences International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.80 19.52 -9.64 -4.29 -12.51
CKLSF
34GF Score
CK Life Sciences International Holdings Inc CKLSF
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CK Life Sciences International Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-16.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-16.8 Mil mean?
CK Life Sciences International Holdings (CKLSF) has a Operating Income of $-16.8 Mil as of Dec. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on CK Life Sciences International Holdings and its competitors.
Is CK Life Sciences International Holdings' Operating Income too high?
CK Life Sciences International Holdings' current Operating Income is $-16.8 Mil. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Operating Income compare to VRTX and REGN?
CK Life Sciences International Holdings' Operating Income of $-16.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current Operating Income is $-16.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current Operating Income of $-16.8 Mil. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current Operating Income is $-16.8 Mil. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Operating Income is $-16.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?

Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued. The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.

Key valuation signals for CKLSF:

  • Operating Income: $-16.8 Mil
  • GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CK Life Sciences International Holdings Business Description

Other Exchanges 00775:Hong Kong
Address 2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score

Get the complete analysis for CKLSF

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price
$0.11
GF Value